Literature DB >> 2088196

Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles.

J Brajtburg1, S Elberg, G S Kobayashi, G Medoff.   

Abstract

Mixed micelles prepared from egg lecithin and the sodium salt of glycocholic acid markedly inhibited amphotericin B toxicity to mammalian cells without significantly affecting the antifungal effects of the drug.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2088196      PMCID： PMC172071          DOI： 10.1128/AAC.34.12.2415

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Amphotericin B: delivery systems.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 2.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

3.  Liposomes prepared dynamically by interactions between bile salt and phospholipid molecules.

Authors:  K Son; H Alkan
Journal:  Biochim Biophys Acta       Date:  1989-06-06

4.  Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations.

Authors:  S Jullien; J Brajtburg; J Bolard
Journal:  Biochim Biophys Acta       Date:  1990-01-15

5.  Preclinical safety evaluation of intravenously administered mixed micelles.

Authors:  K Teelmann; B Schläppi; M Schüpbach; A Kistler
Journal:  Arzneimittelforschung       Date:  1984

6.  Effects of the detergent sucrose monolaurate on binding of amphotericin B to sterols and its toxicity for cells.

Authors:  I Gruda; E Gauthier; S Elberg; J Brajtburg; G Medoff
Journal:  Biochem Biophys Res Commun       Date:  1988-08-15       Impact factor: 3.575

7.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.

Authors:  R Mehta; G Lopez-Berestein; R Hopfer; K Mills; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1984-03-14

8.  Unusual lipid structures selectively reduce the toxicity of amphotericin B.

Authors:  A S Janoff; L T Boni; M C Popescu; S R Minchey; P R Cullis; T D Madden; T Taraschi; S M Gruner; E Shyamsunder; M W Tate
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Comparative bioavailability studies with a new mixed-micelles solution of diazepam utilizing radioreceptor assay, psychometry and EEG brain mapping.

Authors:  B Saletu; P Anderer; K Kinsperger; J Grünberger; W Sieghart
Journal:  Int Clin Psychopharmacol       Date:  1988-10       Impact factor: 1.659

10.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191
  10 in total
  8 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone).

Authors:  G W Sullivan; H T Carper; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Amphotericin B Increases Transglutaminase 2 Expression Associated with Upregulation of Endocytotic Activity in Mouse Microglial Cell Line BV-2.

Authors:  Kenji Kawabe; Katsura Takano; Mitsuaki Moriyama; Yoichi Nakamura
Journal:  Neurochem Res       Date:  2017-02-21       Impact factor: 3.996

5.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

Authors:  J Brajtburg; S Elberg; S J Travis; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.

Authors:  P Y Chavanet; I Garry; N Charlier; D Caillot; J P Kisterman; M D'Athis; H Portier
Journal:  BMJ       Date:  1992-10-17

8.  Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.

Authors:  D Caillot; P Chavanet; O Casasnovas; E Solary; G Zanetta; M Buisson; O Wagner; B Cuisenier; A Bonnin; P Camerlynck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.